Edwards Lifesciences Corporation (NYSE:EW) Receives Consensus Rating of “Moderate Buy” from Analysts

Shares of Edwards Lifesciences Corporation (NYSE:EW) have received a consensus rating of “Moderate Buy” from the twenty-seven ratings firms that are currently covering the company, Marketbeat Ratings reports. Eight research analysts have rated the stock with a hold rating, sixteen have assigned a buy rating and three have given a strong buy rating to the company. The average 12-month price target among analysts that have covered the stock in the last year is $95.9565.

Several brokerages recently weighed in on EW. Weiss Ratings restated a “hold (c)” rating on shares of Edwards Lifesciences in a report on Monday, April 20th. Royal Bank Of Canada restated an “outperform” rating and issued a $100.00 price objective on shares of Edwards Lifesciences in a report on Tuesday. Truist Financial set a $90.00 price objective on shares of Edwards Lifesciences and gave the company a “hold” rating in a report on Friday, April 24th. Wolfe Research upgraded shares of Edwards Lifesciences from a “peer perform” rating to an “outperform” rating and set a $92.00 price objective on the stock in a report on Wednesday, April 1st. Finally, TD Cowen restated a “buy” rating and issued a $104.00 price objective (up from $97.00) on shares of Edwards Lifesciences in a report on Tuesday, June 2nd.

Insider Buying and Selling at Edwards Lifesciences

In related news, VP Daniel J. Lippis sold 1,019 shares of the stock in a transaction that occurred on Friday, May 1st. The shares were sold at an average price of $83.01, for a total value of $84,587.19. Following the transaction, the vice president directly owned 33,934 shares in the company, valued at $2,816,861.34. This represents a 2.92% decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is available at the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, SVP Andrew M. Dahl sold 568 shares of the stock in a transaction that occurred on Friday, May 29th. The shares were sold at an average price of $86.08, for a total transaction of $48,893.44. Following the completion of the transaction, the senior vice president owned 15,334 shares in the company, valued at $1,319,950.72. This represents a 3.57% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. Over the last ninety days, insiders have sold 81,038 shares of company stock valued at $6,683,255. 0.31% of the stock is currently owned by corporate insiders.

Institutional Investors Weigh In On Edwards Lifesciences

Several large investors have recently bought and sold shares of the company. Level Four Advisory Services LLC increased its stake in Edwards Lifesciences by 3.7% in the third quarter. Level Four Advisory Services LLC now owns 3,301 shares of the medical research company’s stock valued at $257,000 after purchasing an additional 119 shares in the last quarter. Colonial Trust Co SC increased its stake in Edwards Lifesciences by 0.4% in the third quarter. Colonial Trust Co SC now owns 32,196 shares of the medical research company’s stock valued at $2,504,000 after purchasing an additional 120 shares in the last quarter. Evermay Wealth Management LLC increased its stake in Edwards Lifesciences by 4.0% in the fourth quarter. Evermay Wealth Management LLC now owns 3,304 shares of the medical research company’s stock valued at $282,000 after purchasing an additional 128 shares in the last quarter. Rehmann Capital Advisory Group increased its stake in Edwards Lifesciences by 2.1% in the fourth quarter. Rehmann Capital Advisory Group now owns 6,399 shares of the medical research company’s stock valued at $546,000 after purchasing an additional 130 shares in the last quarter. Finally, Florida Trust Wealth Management Co increased its stake in Edwards Lifesciences by 1.5% in the fourth quarter. Florida Trust Wealth Management Co now owns 8,810 shares of the medical research company’s stock valued at $751,000 after purchasing an additional 132 shares in the last quarter. Institutional investors own 79.46% of the company’s stock.

Edwards Lifesciences Trading Down 2.3%

EW stock opened at $86.53 on Thursday. The company has a market cap of $49.83 billion, a P/E ratio of 46.03, a PEG ratio of 2.22 and a beta of 0.87. Edwards Lifesciences has a twelve month low of $72.30 and a twelve month high of $89.60. The company has a quick ratio of 3.63, a current ratio of 4.42 and a debt-to-equity ratio of 0.06. The business has a fifty day moving average of $83.14 and a 200-day moving average of $83.11.

Edwards Lifesciences (NYSE:EW) last released its earnings results on Thursday, April 23rd. The medical research company reported $0.78 earnings per share for the quarter, topping analysts’ consensus estimates of $0.73 by $0.05. The company had revenue of $1.65 billion during the quarter, compared to the consensus estimate of $1.60 billion. Edwards Lifesciences had a return on equity of 15.19% and a net margin of 17.39%.The firm’s quarterly revenue was up 16.7% on a year-over-year basis. During the same quarter in the previous year, the company posted $0.64 earnings per share. Edwards Lifesciences has set its FY 2026 guidance at 2.950-3.050 EPS and its Q2 2026 guidance at 0.700-0.760 EPS. As a group, equities research analysts expect that Edwards Lifesciences will post 3 EPS for the current year.

About Edwards Lifesciences

Edwards Lifesciences is a medical technology company focused on products and therapies for structural heart disease and critical care monitoring. The company designs, develops and manufactures prosthetic heart valves and related delivery systems used in both surgical and minimally invasive (transcatheter) procedures. Its portfolio addresses a range of valvular conditions, with an emphasis on technologies that enable transcatheter aortic valve replacement (TAVR) as an alternative to open-heart surgery.

In addition to transcatheter heart valves—including the widely recognized SAPIEN family—Edwards offers surgical tissue valves and ancillary devices used by cardiac surgeons, interventional cardiologists and hospital teams.